QC Kinetix is a rapidly growing regenerative medicine leader offering innovative, non-surgical solutions for joint pain relief. Since its inception in 2017, the company has experienced exponential growth, establishing itself in over 100 cities nationwide and treating thousands of patients with cutting-edge therapies.
Harnessing the body’s natural ability to heal, QC Kinetix’s treatments improve functionality and reduce discomfort without the need for surgery.
In May 2024, Entrepreneur recognized QC Kinetix as one of its top 10 New and Emerging Franchises, ranking it No. 9 due to remarkable unit growth, financial strength, and brand power. Over the past three years, the company has achieved a staggering 2,111% unit growth, cementing its position among the industry’s top brands.
“We’re honored to rank among some of the fastest-growing franchise brands,” shared QC Kinetix’s CEO. “This recognition is a testament to our team’s hard work and dedication. I’m excited to see our brand continue to grow and redefine regenerative medicine.”
The QC Kinetix Mission: Improving Lives Without Surgery
Dedicated to offering superior alternatives for pain management, QC Kinetix strives to help patients regain their quality of life without relying on surgery, steroids, or addictive medications. Their success lies in leveraging unique biologics treatment protocols, a hallmark of their commitment to patient care.
The company recently welcomed renowned orthopedic surgeon Dr. Mitchell Sheinkop as its national medical director. With over 37 years of experience in joint replacement surgery, Dr. Sheinkop is now leading QC Kinetix’s medical management team. His focus includes refining treatment protocols, spearheading research and development, and integrating physical therapy and weight loss into the company’s existing treatment models.
“I’m excited to bring my expertise to QC Kinetix and further the mission of transforming regenerative medicine,” Dr. Sheinkop remarked.
QC Kinetix has also garnered the support of prominent athletes like Pro Football Hall of Famer Emmitt Smith, who serves as the company’s national spokesperson.
“I’ve got to keep taking care of these joints,” said Smith. “When I take QC Kinetix natural supplements, it’s like – bam – Emmitt 2.0. Sometimes, you need a competitive edge.”
The Vision Behind QC Kinetix
Founded by a team of medical and business professionals in Charlotte, North Carolina (the “Queen City”), QC Kinetix represents a bold challenge to traditional pain management methods. By employing regenerative medicine and a concierge medical model, they prioritize research-driven, patient-focused solutions.
“No longer did we want insurance to dictate treatment options,” explained a company spokesperson. “Our mission is to become the go-to choice for pain management—not the last resort.”
By addressing musculoskeletal pain through natural biologics, QC Kinetix enables patients to avoid invasive surgeries, harmful medications, and steroids.
Delivering Patient-Centered Treatment
QC Kinetix is redefining healthcare by helping patients maintain active lifestyles. Their advanced biologic treatments harness the body’s natural healing capabilities, offering a non-invasive approach to musculoskeletal pain.
In 2023, QC Kinetix surpassed $100 million in system-wide sales, and by April 2024, they had treated over 40,000 patients nationwide.
“It is our goal to change medicine,” shared the CEO. “We measure success by our ability to transform lives. By prioritizing patient care, growth and profitability naturally follow.”
Expansion on a Global Scale
With a strong presence across the U.S., QC Kinetix is eyeing international markets, including the UK, Australia, and New Zealand. The company aims to have 250 operational locations in the U.S. by the end of 2024.
Despite their rapid success, QC Kinetix’s CEO believes the company’s growth could be even faster, given the increasing demand for alternatives to surgery and pain medications.
“I love this brand and our future,” he stated. “It’s about impacting lives and being a true game-changer in the medical field.”
